New drug PRO-203 enters first human safety trials for scleroderma
Disease control
Recruiting now
This early-stage study tests the safety of a new drug called PRO-203 in 74 people. First, healthy volunteers receive a single injection to check for side effects. Then, people with systemic sclerosis (a chronic autoimmune disease causing skin and organ hardening) receive the drug…
Phase: PHASE1 • Sponsor: Prolium Bioscience, Inc • Aim: Disease control
Last updated Jun 15, 2026 18:57 UTC